Conferences

International Liver Congress – 2015

The International Liver Congress 2015 (ILC 2015), the 50th annual meeting of the European Association for the Study of the Liver (EASL), took place in Vienna, Austria, 22nd-26th April 2015.
Hepatitis C treatment

Sofosbuvir/ledipasvir plus ribavirin shows high cure rate for hepatitis C patients with advanced liver disease

Hepatitis C treatment

New EASL guidelines prioritise interferon-free hepatitis C treatment

Hepatitis C treatment

Liver function and survival improve after treatment with Viekirax + Exviera regimen

Hepatitis B

Hepatitis B and C co-infection linked to worse liver fibrosis than hepatitis B alone

Hepatitis C transmission & prevention

Hepatitis C treatment could halve HCV transmission among gay men in UK over 10 years

Hepatitis C transmission & prevention

Reinfection after hepatitis C cure: prevention may require long-term support for people who have injected drugs

Hepatitis C treatment

Hepatitis C treatment for people in prison may be highly cost-effective in England

Hepatitis C treatment

Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis

Hepatitis C treatment

Civacir immune globulin may help prevent HCV reinfection after liver transplant

New & experimental hepatitis C treatment

Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

New & experimental hepatitis C treatment

Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients

Cancer

People with hepatitis C have higher cancer rates, even when excluding liver cancer

New & experimental hepatitis C treatment

Sofosbuvir-based therapy effective for hepatitis C patients with decompensated cirrhosis

New & experimental hepatitis C treatment

Gilead triple combination cures easy-to-treat hepatitis C patients in 6 weeks, but 4 weeks is not enough

Hepatitis C treatment

Another study confirms detrimental effects of delaying hepatitis C treatment

New & experimental hepatitis C treatment

When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

Hepatitis C treatment

Sofosbuvir-based treatment safe and effective in advanced kidney disease

Hepatitis C treatment

Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease

Hepatitis C treatment

Sofosbuvir plus pegylated interferon/ribavirin is highly effective for people with hard-to-treat genotype 3 hepatitis C

New & experimental hepatitis C treatment

Sofosbuvir, daclatasvir and ribavirin cures hepatitis C for most people with advanced cirrhosis or liver transplants

Hepatitis C symptoms & diagnosis

Alcohol misuse the strongest predictor of severe liver damage and death in French people with hepatitis C

Hepatitis B

Expanded vaccination and treatment could help eliminate hepatitis B worldwide

Hepatitis C symptoms & diagnosis

Advanced liver damage is common in people with undiagnosed hepatitis C in US survey

New & experimental hepatitis C treatment

Grazoprevir/elbasvir highly effective in treatment-experienced and HIV-coinfected hepatitis C patients

New & experimental hepatitis C treatment

Grazoprevir / elbasvir highly effective in previously untreated hepatitis C

New & experimental hepatitis C treatment

Merck HCV combination achieves 90% cure in advanced cirrhosis

New & experimental hepatitis C treatment

Merck HCV combination effective after failure of first generation of direct-acting antivirals